Academic literature on the topic '004.89: 621.396'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic '004.89: 621.396.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "004.89: 621.396"

1

Sasaki, Koji, Ildefonso Ismael Rodriguez-Rivera, Hagop M. Kantarjian, et al. "Correlation of Lymphocyte Count with Treatment Response to Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase." Blood 124, no. 21 (2014): 4538. http://dx.doi.org/10.1182/blood.v124.21.4538.4538.

Full text
Abstract:
Abstract Background: Total lymphocyte count (TLC) has been shown to correlate with outcomes in patients (pts) with acute leukemia. The clinical correlation to TLC in pts with chronic myeloid leukemia in chronic phase (CML-CP) who were treated with a tyrosine-kinase inhibitor (TKI) is unclear. Methods: Lymphocyte data in pts with newly diagnosed CML-CP who were enrolled in consecutive or parallel clinical trials with front-line imatinib (IM), nilotinib (Nilo), or dasatinib (Dasa) were collected at the time of diagnosis, and 3 and 6 months (M) after the start of TKI. Relative lymphocytrosis (RLC
APA, Harvard, Vancouver, ISO, and other styles
2

Rodriguez, Lisette Patricia, Vida Farhangi, Julaine Braham, Robert A. Smith, and Wilhelmine Wiese-Rometsch. "In-Hospital Glycemic Dysregulation Associated With Worse Outcomes in COVID-19." Journal of the Endocrine Society 5, Supplement_1 (2021): A346. http://dx.doi.org/10.1210/jendso/bvab048.705.

Full text
Abstract:
Abstract Introduction: Evidence establishes that COVID-19 patients with DM2 are at increased risk for severe disease and worse outcomes. Peer reviewed data is sparse comparing glycemic control and clinical outcomes among COVID-19 patients with vs. without DM2, and thus we sought to address this gap. Methods: We selected patients at least 18 years old who expired or were discharged between March 16, 2020 through September 15, 2020. Principal analysis compared glycemic patterns among patients with DM2 vs. non-DM2. Median, coefficient of variation (CV), maximum and minimum glucose parameters were
APA, Harvard, Vancouver, ISO, and other styles
3

Grotle, Margreth, Lars Christian Bråten, Jens Ivar Brox, et al. "Cost–utility analysis of antibiotic treatment in patients with chronic low back pain and Modic changes: results from a randomised, placebo-controlled trial in Norway (the AIM study)." BMJ Open 10, no. 6 (2020): e035461. http://dx.doi.org/10.1136/bmjopen-2019-035461.

Full text
Abstract:
ObjectiveTo evaluate the cost–utility of 100 days of antibiotics in patients with chronic low back pain (LBP) and type I or II Modic changes included in the Antibiotic treatment In patients with chronic low back pain and Modic changes (AIM) study.DesignA cost–utility analysis from a societal and healthcare perspective alongside a double-blinded, parallel group, placebo, multicentre trial.SettingHospital outpatient clinics at six hospitals in Norway. The main results from the AIM study showed a small effect in back-related disability in favour of the antibiotics group, and slightly larger in th
APA, Harvard, Vancouver, ISO, and other styles
4

Diorio, Caroline, Kevin O. McNerney, Michele Lambert, et al. "Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations." Blood Advances 4, no. 23 (2020): 6051–63. http://dx.doi.org/10.1182/bloodadvances.2020003471.

Full text
Abstract:
Abstract Most children with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have mild or minimal disease, with a small proportion developing severe disease or multisystem inflammatory syndrome in children (MIS-C). Complement-mediated thrombotic microangiopathy (TMA) has been associated with SARS-CoV-2 infection in adults but has not been studied in the pediatric population. We hypothesized that complement activation plays an important role in SARS-CoV-2 infection in children and sought to understand if TMA was present in these patients. We enrolled 50 hospitalized pediat
APA, Harvard, Vancouver, ISO, and other styles
5

Josa-Laorden, Claudia, Anxela Crestelo-Vieitez, María García Andreu, et al. "Gender-Based Differences by Age Range in Patients Hospitalized with COVID-19: A Spanish Observational Cohort Study." Journal of Clinical Medicine 10, no. 5 (2021): 899. http://dx.doi.org/10.3390/jcm10050899.

Full text
Abstract:
There is some evidence that male gender could have a negative impact on the prognosis and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The aim of the present study was to compare the characteristics of coronavirus disease 2019 (COVID-19) between hospitalized men and women with confirmed SARS-CoV-2 infection. This multicenter, retrospective, observational study is based on the SEMI-COVID-19 Registry. We analyzed the differences between men and women for a wide variety of demographic, clinical, and treatment variables, and the sex distribution of the report
APA, Harvard, Vancouver, ISO, and other styles
6

Prieto-Peña, D., S. Remuzgo Martinez, F. Genre, et al. "POS0113 BAFF-APRIL-BAFFR PATHWAY ON THE PATHOGENESIS OF IMMUNOGLOBULIN-A VASCULITIS." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 267.2–268. http://dx.doi.org/10.1136/annrheumdis-2021-eular.707.

Full text
Abstract:
Background:BAFF, APRIL and BAFFR are genes that encode cytokines with a key role in the development and survival of B-lymphocytes [1-4]: The B cell-activating factor (BAFF, also known as BLyS), a proliferation-inducing ligand (APRIL) and BAFF receptor (BAFF-R), respectively. Previous genetic studies have revealed that the BAFF-APRIL-BAFFR pathway is implicated in the genetic predisposition to several immune-mediated diseases [5].Objectives:To determine whether the BAFF-APRIL-BAFFR pathway represents a novel genetic risk factor for the pathogenesis of Immunoglobulin-A vasculitis (IgAV), an infl
APA, Harvard, Vancouver, ISO, and other styles
7

Alsheekh, Ahmad, Anil Hingorani, Samson Ferm, et al. "Is there an effect of race/ethnicity on early complications of iliac vein stenting?" Vascular 25, no. 5 (2017): 549–52. http://dx.doi.org/10.1177/1708538117699335.

Full text
Abstract:
Background There have been well-documented implications of race/ethnicity on the outcome of various vascular diseases. Little literature has examined the effect of race/ethnicity on venous disease. Iliac vein stenting is an emerging technology in treating chronic venous insufficiency. To further characterize this disease and its treatment, we chose to study the effect of selected clinical factors including race/ethnicity on the early complications of non-thrombotic iliac vein stenting. Methods In this observational study, data analysis was performed for 623 patients with chronic venous insuffi
APA, Harvard, Vancouver, ISO, and other styles
8

Chan, C. W. S., P. H. LI, C. S. Lau, and H. Y. Chung. "POS1015 ANTI-TNF DRUGS AND CARDIOVASCULAR EVENTS IN PATIENTS WITH SPONDYLOARTHRITIS." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 775.2–776. http://dx.doi.org/10.1136/annrheumdis-2021-eular.4133.

Full text
Abstract:
Background:Cardiovascular (CVS) diseases are the leading cause of death worldwide and patients with rheumatic diseases have an increased CVS risk including stroke and myocardial infarction (MI) (1-3). CVS risk factors and CVS events are common in SpA (4). Delineating the CVS risk and the association with medications in patients with SpA would be useful.Objectives:The objective of this study was to delineate the CVS risk and the association with medications in patients with SpA.Methods:Patients with SpA and patients with non-specific back pain (NSBP) were identified in rheumatology and orthoped
APA, Harvard, Vancouver, ISO, and other styles
9

Cholankeril, Michelle, Donald Hoover, Shanti Srinivas, et al. "Non-Hodgkin’s (NHL) Lymphoma Patients(pts) in the VA Population: Clinical Characteristics and Survival Predictors." Blood 110, no. 11 (2007): 4435. http://dx.doi.org/10.1182/blood.v110.11.4435.4435.

Full text
Abstract:
Abstract Background: To describe the clinical characteristics (CC) and survival predictors in NHL pts at a VA medical center. Methods: We performed a retrospective chart review of all pts diagnosed with Non Hodgkin’s lymphoma at the VANJHCS from January 1, 1997 through December 31, 2006. Records were reviewed for demographic, clinical, pathological data and survival. Statistical analyses were performed using STATA. The study was approved by the IRB. Results: 1. Clinical characteristics. There were 92 pts, with 57 deaths(62%). The median (M) age was 62 years (range 27–89). The race distribution
APA, Harvard, Vancouver, ISO, and other styles
10

Giné, Eva, Sílvia Beà, Alba Navarro, et al. "Risk of Central Nervous System (CNS) Involvement in Patients with Mantle Cell Lymphoma (MCL): Analysis of Clinico-Biological Factors in a Series of 283 Cases." Blood 124, no. 21 (2014): 1677. http://dx.doi.org/10.1182/blood.v124.21.1677.1677.

Full text
Abstract:
Abstract Introduction: MCL is a mature B-cell neoplasm characterized by t(11;14) (q13;q32) and cyclin D1 (CCND1) overexpression. Molecular studies have revealed other alterations in cell-cycle regulation, DNA damage response and cell survival pathways, with a landscape of somatic mutations being recently identified. CNS involvement is a well known complication, occurring in 4-26% of MCL at five years, with an ominous significance. Although different clinical variables have been identified as risk factors for CNS infiltration, the biological parameters related to this complication have not been
APA, Harvard, Vancouver, ISO, and other styles
More sources
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!